Difference between revisions of "Part:BBa K1202008"
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
| − | |||
__NOTOC__ | __NOTOC__ | ||
<partinfo>BBa_K1202008 short</partinfo> | <partinfo>BBa_K1202008 short</partinfo> | ||
| − | + | E4orf4 is a novel prospective cancer drug which induces programmed cell death (apoptosis) phase of normal cell life cycle in cancer cells, selectively. The exact mechanism of e4orf4 is not understood, yet. But, the efficiency and results of the function are researched and pose promising hopeful results for efficient cancer therapy. | |
| + | |||
| + | This protein is planned as alternative for apoptin cancer killing peptide. | ||
<!-- Add more about the biology of this part here | <!-- Add more about the biology of this part here | ||
Latest revision as of 23:31, 4 October 2013
E4orf4
E4orf4 is a novel prospective cancer drug which induces programmed cell death (apoptosis) phase of normal cell life cycle in cancer cells, selectively. The exact mechanism of e4orf4 is not understood, yet. But, the efficiency and results of the function are researched and pose promising hopeful results for efficient cancer therapy.
This protein is planned as alternative for apoptin cancer killing peptide.
Sequence and Features
Assembly Compatibility:
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25INCOMPATIBLE WITH RFC[25]Illegal NgoMIV site found at 9
Illegal NgoMIV site found at 18 - 1000COMPATIBLE WITH RFC[1000]